These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
    Author: Cremerius U, Fabry U, Kröll U, Zimny M, Neuerburg J, Osieka R, Büll U.
    Journal: Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778.
    Abstract:
    AIM: Of the present retrospective study was to validate the clinical value of FDG-PET for therapy control of malignant lymphoma. METHOD: 72 patients (41 non-Hodgkin lymphomas, 29 Hodgkin's disease, 2 unclassified) received static FDG-PET scans of initially involved regions (n = 53) or of the entire neck and trunk (n = 19) after therapy. CT imaging (n = 70) and serum LDH measurement (n = 64) were also performed. Results were validated either by biopsy (n = 7) or by clinical follow-up (n = 65). The predictive value of PET was analysed in relation to different prognostic factors (stage, recurrence status, number of prior therapy regimen). RESULTS: PET obtained a sensitivity of 88%, a specificity of 83% and an overall accuracy of 85% for detection of residual disease. The values for CT were 84%, 31% resp. 54%, and for serum LDH 50%, 92% and 73%. The predictive value of PET was related to the prevalence of residual disease. PET predicted complete remission in more than 90% of patients with moderate risk (stage I-III, no relapse, no more than two different therapy regimens). In high risk patients, however, the negative predictive value of PET was 50-67%. CONCLUSION: FDG-PET is more accurate than CT imaging and LDH measurement for therapy monitoring of malignant lymphoma. Therapy success can be reliably predicted in patients with moderate risk.
    [Abstract] [Full Text] [Related] [New Search]